Your browser doesn't support javascript.
loading
Subcutaneous lacosamide for continuous focal seizures.
Crispin, Helen; Otway, Victoria; Morris, Rhiannon.
Affiliation
  • Crispin H; Palliative Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK helen.crispin@uhs.nhs.uk.
  • Otway V; Palliative Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Morris R; Neurology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Article in En | MEDLINE | ID: mdl-38851242
ABSTRACT
Management of continuous focal seizure activity provides a unique challenge in palliative medicine. In cases where the patient is conscious and would prefer to remain so, we need to balance seizure-control with the sedating side effects of anti-seizure medications. Here we present a case in which subcutaneous lacosamide was given as part of a multi-modal treatment regime for a patient with continuous focal seizure activity. Lacosamide is a relatively new anti-seizure medication, that, unlike some anticonvulsants, has few drug interactions, is relatively non-sedating, and has physicochemical properties compatible with administration by the subcutaneous route. This case report adds to the very limited existing literature on the administration of lacosamide by the subcutaneous route. We conclude that lacosamide potentially provides an attractive option to contribute to the individualised care of this group of patients, and it may also have a role in the management of neuropathic pain where the enteral route is not available.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BMJ Support Palliat Care Year: 2024 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BMJ Support Palliat Care Year: 2024 Document type: Article Country of publication: United kingdom